Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Blinatumomab> ?p ?o }
- Blinatumomab abstract "Blinatumomab (trade name Blincyto, previously known as AMG103) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014 it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval. When it launched, blinatumomab was priced at $178,000 per year in the United States; only about 1,000 people were eligible to take the drug, based on its label.".
- Blinatumomab atcPrefix "L01".
- Blinatumomab atcSuffix "XC19".
- Blinatumomab bioavailability "100.0".
- Blinatumomab casNumber "853426-35-4".
- Blinatumomab fdaUniiCode "4FR53SIF3A".
- Blinatumomab thumbnail BiTE_antibody_en.svg?width=300.
- Blinatumomab wikiPageExternalLink blincyto_pi_hcp_english.pdf.
- Blinatumomab wikiPageExternalLink www.blincyto.com.
- Blinatumomab wikiPageExternalLink results?term=blinatumomab.
- Blinatumomab wikiPageID "18875843".
- Blinatumomab wikiPageLength "8681".
- Blinatumomab wikiPageOutDegree "41".
- Blinatumomab wikiPageRevisionID "698503935".
- Blinatumomab wikiPageWikiLink Acute_lymphoblastic_leukemia.
- Blinatumomab wikiPageWikiLink Amgen.
- Blinatumomab wikiPageWikiLink Antigen.
- Blinatumomab wikiPageWikiLink Atomic_mass_unit.
- Blinatumomab wikiPageWikiLink B_cell.
- Blinatumomab wikiPageWikiLink Bi-specific_T-cell_engager.
- Blinatumomab wikiPageWikiLink Biologic_license_application.
- Blinatumomab wikiPageWikiLink Biopharmaceutical.
- Blinatumomab wikiPageWikiLink CD19.
- Blinatumomab wikiPageWikiLink CD3_(immunology).
- Blinatumomab wikiPageWikiLink Category:Breakthrough_therapy.
- Blinatumomab wikiPageWikiLink Category:Immunology.
- Blinatumomab wikiPageWikiLink Category:Monoclonal_antibodies_for_tumors.
- Blinatumomab wikiPageWikiLink Cytotoxicity.
- Blinatumomab wikiPageWikiLink FDA_Accelerated_Approval.
- Blinatumomab wikiPageWikiLink Food_and_Drug_Administration.
- Blinatumomab wikiPageWikiLink Lonza_Group.
- Blinatumomab wikiPageWikiLink Malignancy.
- Blinatumomab wikiPageWikiLink Micromet.
- Blinatumomab wikiPageWikiLink Monoclonal_antibody.
- Blinatumomab wikiPageWikiLink Pembrolizumab.
- Blinatumomab wikiPageWikiLink Philadelphia_chromosome.
- Blinatumomab wikiPageWikiLink T_cell.
- Blinatumomab wikiPageWikiLink T_cell_receptor.
- Blinatumomab wikiPageWikiLink Therapy.
- Blinatumomab wikiPageWikiLink File:BiTE_antibody_en.svg.
- Blinatumomab wikiPageWikiLinkText "Blinatumomab".
- Blinatumomab wikiPageWikiLinkText "Blincyto (Blinatumomab)".
- Blinatumomab wikiPageWikiLinkText "blinatumomab".
- Blinatumomab atcPrefix "L01".
- Blinatumomab atcSuffix "XC19".
- Blinatumomab bioavailability "100.0".
- Blinatumomab c "2367".
- Blinatumomab casNumber "853426".
- Blinatumomab chemspiderid "none".
- Blinatumomab eliminationHalfLife "7596.0".
- Blinatumomab excretion "urine".
- Blinatumomab h "3577".
- Blinatumomab legalUs "Rx-only".
- Blinatumomab mabType "BiTE".
- Blinatumomab metabolism "degradation into small peptides and amino acids".
- Blinatumomab molecularWeight "54.1".
- Blinatumomab n "649".
- Blinatumomab o "772".
- Blinatumomab pregnancyUs "C".
- Blinatumomab routesOfAdministration "intravenous".
- Blinatumomab s "19".
- Blinatumomab source "o".
- Blinatumomab target CD19.
- Blinatumomab target CD3_(immunology).
- Blinatumomab tradename "Blincyto".
- Blinatumomab type "mab".
- Blinatumomab unii "4".
- Blinatumomab verifiedfields "changed".
- Blinatumomab verifiedrevid "459980828".
- Blinatumomab wikiPageUsesTemplate Template:Cascite.
- Blinatumomab wikiPageUsesTemplate Template:Chemspidercite.
- Blinatumomab wikiPageUsesTemplate Template:Drugbankcite.
- Blinatumomab wikiPageUsesTemplate Template:Drugbox.
- Blinatumomab wikiPageUsesTemplate Template:Fdacite.
- Blinatumomab wikiPageUsesTemplate Template:Monoclonals_for_tumors.
- Blinatumomab wikiPageUsesTemplate Template:Reflist.
- Blinatumomab subject Category:Breakthrough_therapy.
- Blinatumomab subject Category:Immunology.
- Blinatumomab subject Category:Monoclonal_antibodies_for_tumors.
- Blinatumomab hypernym Drug.
- Blinatumomab type ChemicalSubstance.
- Blinatumomab type Drug.
- Blinatumomab type Antibody.
- Blinatumomab type Chemical.
- Blinatumomab type Drug.
- Blinatumomab type ChemicalObject.
- Blinatumomab type Thing.
- Blinatumomab type Q8386.
- Blinatumomab comment "Blinatumomab (trade name Blincyto, previously known as AMG103) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells.".
- Blinatumomab label "Blinatumomab".
- Blinatumomab sameAs Q410189.
- Blinatumomab sameAs بليناتوموماب.
- Blinatumomab sameAs Blinatumomab.
- Blinatumomab sameAs Blinatumomab.
- Blinatumomab sameAs Blinatumomab.
- Blinatumomab sameAs בלינטומומב.
- Blinatumomab sameAs Blinatumomab.
- Blinatumomab sameAs m.04gm0f3.
- Blinatumomab sameAs Q410189.
- Blinatumomab wasDerivedFrom Blinatumomab?oldid=698503935.